Healthcare Sector: Is Crispr Therapeutics AG (CRSP) A Winner?

Tuesday, February 11, 2020 10:42 AM | InvestorsObserver Analysts

The 68 rating InvestorsObserver gives to Crispr Therapeutics AG (CRSP) stock puts it near the top of the Healthcare sector.

In addition to scoring higher than 86 percent of stocks in the Healthcare sector, CRSP’s 68 overall rating means the stock scores better than 68 of all stocks.

Overall Score - 68
CRSP has an Overall Score of 68. Find out what this means to you and get the rest of the rankings on CRSP!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies in the healthcare sector can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the best stocks in that sector.

Not only are these scores easy to understand, but it is easy to compare stocks to each other. You can find the best stock in healthcare or look for the sector that has the highest average score.

The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.)

What's Happening With Crispr Therapeutics AG Stock Today?

Crispr Therapeutics AG (CRSP) stock has fallen -0.69% while the S&P 500 has gained 0.69% as of 10:33 AM on Tuesday, Feb 11. CRSP is down -$0.39 from the previous closing price of $56.62 on volume of 375,983 shares. Over the past year the S&P 500 is up 24.56% while CRSP has gained 80.63%. CRSP lost -$0.46 per share the over the last 12 months.

To screen for more stocks like CRSP click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Sector Update: Health Care

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Is Twist Bioscience Corp (TWST) Stock About to Get Hot Tuesday?

Do Traders View Takeda Pharmaceutical Co Ltd (TAK) Stock's Current Trend Positively?

Should You Buy Quotient Ltd (QTNT) Stock After it Has Fallen 2.82% in a Week?

Related Companies